哥伦比亚睡眠呼吸暂停患者的存活率及与死亡率相关的风险因素：一项回顾性队列研究

IF 3 2区医学 Q2 CLINICAL NEUROLOGY

Nature and Science of Sleep Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI:10.2147/NSS.S481010

Eduardo Tuta-Quintero, Alirio R Bastidas, Kamil Faizal-Gómez, Sergio Guillermo Torres-Riveros, Diego Alejandro Rodríguez-Barajas, Jonathan Alexander Guezguan, Laura D Muñoz, Ana Carolina Rojas, Katherine Hernández Calderón, Natalia Valentina Ardila Velasco, Paula Prieto, Juliana Cuestas, Julian Camacho-Osorio, Gabriela Bonilla, Estefania Collazos Bahamon, María Alejandra Guardiola, David Luna Salazar, Lina Paola Fajardo, Johan Rincón-Hernández

{"title":"哥伦比亚睡眠呼吸暂停患者的存活率及与死亡率相关的风险因素：一项回顾性队列研究","authors":"Eduardo Tuta-Quintero, Alirio R Bastidas, Kamil Faizal-Gómez, Sergio Guillermo Torres-Riveros, Diego Alejandro Rodríguez-Barajas, Jonathan Alexander Guezguan, Laura D Muñoz, Ana Carolina Rojas, Katherine Hernández Calderón, Natalia Valentina Ardila Velasco, Paula Prieto, Juliana Cuestas, Julian Camacho-Osorio, Gabriela Bonilla, Estefania Collazos Bahamon, María Alejandra Guardiola, David Luna Salazar, Lina Paola Fajardo, Johan Rincón-Hernández","doi":"10.2147/NSS.S481010","DOIUrl":null,"url":null,"abstract":"Background: Survival in patients with sleep apnoea (SA) can be reduced by variables such as age, sex, and comorbidities. However, survival data in patients with SA in Colombia remains scarce.Methods: This is a retrospective cohort study of patients diagnosed with SA between 2005 and 2022. Five-year survival was assessed using the Kaplan-Meier method, and survival curves were stratified by age, sex, and cardiovascular disease. Risk factors associated with survival were evaluated using Hazard Ratio (HR) by adjusting for confounding variables with a Cox regression model. A minimum sample size of 1537 patients were estimated to be necessary to estimate a survival incidence rate with a 5% precision.Results: The five-year survival rate in the general population was 94.6%, with lower survival in patients over 65 years (88.5% vs 97.9%; p < 0.001) and in patients with cardiovascular disease (89% vs 95.2%; p < 0.001) compared to the control group. In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02-1.07; p < 0.001). Male sex had an HR of 2.31 (95% CI: 1.25-4.25; p = 0.007), congestive heart failure an HR of 4.00 (95% CI: 2.31-6.94; p < 0.001), chronic obstructive pulmonary disease (COPD) an HR of 1.75 (95% CI: 1.04-2.96; p = 0.035), chronic kidney disease (CKD) an HR of 2.23 (95% CI: 1.31-3.78; p = 0.003), and metastatic cancer an HR of 4.96 (95% CI: 1.95-12.60; p = 0.001).Conclusion: The study showed a high five-year survival rate in patients with SA. The risk factors associated with decreased overall five-year survival were age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer.","PeriodicalId":18896,"journal":{"name":"Nature and Science of Sleep","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470772/pdf/","citationCount":"0","resultStr":"{\"title\":\"Survival and Risk Factors Associated with Mortality in Patients with Sleep Apnoea in Colombia: A Retrospective Cohort Study.\",\"authors\":\"Eduardo Tuta-Quintero, Alirio R Bastidas, Kamil Faizal-Gómez, Sergio Guillermo Torres-Riveros, Diego Alejandro Rodríguez-Barajas, Jonathan Alexander Guezguan, Laura D Muñoz, Ana Carolina Rojas, Katherine Hernández Calderón, Natalia Valentina Ardila Velasco, Paula Prieto, Juliana Cuestas, Julian Camacho-Osorio, Gabriela Bonilla, Estefania Collazos Bahamon, María Alejandra Guardiola, David Luna Salazar, Lina Paola Fajardo, Johan Rincón-Hernández\",\"doi\":\"10.2147/NSS.S481010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Survival in patients with sleep apnoea (SA) can be reduced by variables such as age, sex, and comorbidities. However, survival data in patients with SA in Colombia remains scarce.Methods: This is a retrospective cohort study of patients diagnosed with SA between 2005 and 2022. Five-year survival was assessed using the Kaplan-Meier method, and survival curves were stratified by age, sex, and cardiovascular disease. Risk factors associated with survival were evaluated using Hazard Ratio (HR) by adjusting for confounding variables with a Cox regression model. A minimum sample size of 1537 patients were estimated to be necessary to estimate a survival incidence rate with a 5% precision.Results: The five-year survival rate in the general population was 94.6%, with lower survival in patients over 65 years (88.5% vs 97.9%; p < 0.001) and in patients with cardiovascular disease (89% vs 95.2%; p < 0.001) compared to the control group. In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02-1.07; p < 0.001). Male sex had an HR of 2.31 (95% CI: 1.25-4.25; p = 0.007), congestive heart failure an HR of 4.00 (95% CI: 2.31-6.94; p < 0.001), chronic obstructive pulmonary disease (COPD) an HR of 1.75 (95% CI: 1.04-2.96; p = 0.035), chronic kidney disease (CKD) an HR of 2.23 (95% CI: 1.31-3.78; p = 0.003), and metastatic cancer an HR of 4.96 (95% CI: 1.95-12.60; p = 0.001).Conclusion: The study showed a high five-year survival rate in patients with SA. The risk factors associated with decreased overall five-year survival were age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer.\",\"PeriodicalId\":18896,\"journal\":{\"name\":\"Nature and Science of Sleep\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470772/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature and Science of Sleep\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/NSS.S481010\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature and Science of Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/NSS.S481010","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：睡眠呼吸暂停（SA）患者的存活率会因年龄、性别和合并症等变量而降低。然而，哥伦比亚睡眠呼吸暂停患者的存活率数据仍然很少：这是一项回顾性队列研究，研究对象为 2005 年至 2022 年间确诊的 SA 患者。采用卡普兰-梅耶法评估了五年生存率，并根据年龄、性别和心血管疾病对生存曲线进行了分层。通过考克斯回归模型调整混杂变量，使用危险比（HR）评估与生存相关的风险因素。据估计，要估算出精确度为5%的存活率，至少需要1537名患者的样本量：普通人群的五年生存率为94.6%，与对照组相比，65岁以上患者（88.5% vs 97.9%；P < 0.001）和心血管疾病患者（89% vs 95.2%；P < 0.001）的生存率较低。在考克斯回归中，年龄的 HR 值为 1.05（95% CI：1.02-1.07；p < 0.001）。男性的 HR 为 2.31 (95% CI: 1.25-4.25; p = 0.007)，充血性心力衰竭的 HR 为 4.00 (95% CI: 2.31-6.94; p < 0.001)，慢性阻塞性肺病（COPD）的 HR 为 1.75 (95% CI: 1.04-2.96; p = 0.035)，慢性肾脏疾病（CKD）的HR为2.23 (95% CI: 1.31-3.78; p = 0.003)，转移性癌症的HR为4.96 (95% CI: 1.95-12.60; p = 0.001)：研究显示，SA 患者的五年生存率较高。结论：该研究显示，SA 患者的五年生存率较高，与五年总生存率下降相关的风险因素包括年龄、男性、心血管疾病、慢性阻塞性肺病、慢性肾脏病和转移性癌症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Survival and Risk Factors Associated with Mortality in Patients with Sleep Apnoea in Colombia: A Retrospective Cohort Study.

Background: Survival in patients with sleep apnoea (SA) can be reduced by variables such as age, sex, and comorbidities. However, survival data in patients with SA in Colombia remains scarce.

Methods: This is a retrospective cohort study of patients diagnosed with SA between 2005 and 2022. Five-year survival was assessed using the Kaplan-Meier method, and survival curves were stratified by age, sex, and cardiovascular disease. Risk factors associated with survival were evaluated using Hazard Ratio (HR) by adjusting for confounding variables with a Cox regression model. A minimum sample size of 1537 patients were estimated to be necessary to estimate a survival incidence rate with a 5% precision.

Results: The five-year survival rate in the general population was 94.6%, with lower survival in patients over 65 years (88.5% vs 97.9%; p < 0.001) and in patients with cardiovascular disease (89% vs 95.2%; p < 0.001) compared to the control group. In the Cox regression, age showed an HR of 1.05 (95% CI: 1.02-1.07; p < 0.001). Male sex had an HR of 2.31 (95% CI: 1.25-4.25; p = 0.007), congestive heart failure an HR of 4.00 (95% CI: 2.31-6.94; p < 0.001), chronic obstructive pulmonary disease (COPD) an HR of 1.75 (95% CI: 1.04-2.96; p = 0.035), chronic kidney disease (CKD) an HR of 2.23 (95% CI: 1.31-3.78; p = 0.003), and metastatic cancer an HR of 4.96 (95% CI: 1.95-12.60; p = 0.001).

Conclusion: The study showed a high five-year survival rate in patients with SA. The risk factors associated with decreased overall five-year survival were age, male sex, cardiovascular disease, COPD, CKD, and metastatic cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature and Science of Sleep Neuroscience-Behavioral Neuroscience

CiteScore

5.70

自引率

5.90%

发文量

245

审稿时长

16 weeks

期刊介绍： Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. Specific topics covered in the journal include: The functions of sleep in humans and other animals Physiological and neurophysiological changes with sleep The genetics of sleep and sleep differences The neurotransmitters, receptors and pathways involved in controlling both sleep and wakefulness Behavioral and pharmacological interventions aimed at improving sleep, and improving wakefulness Sleep changes with development and with age Sleep and reproduction (e.g., changes across the menstrual cycle, with pregnancy and menopause) The science and nature of dreams Sleep disorders Impact of sleep and sleep disorders on health, daytime function and quality of life Sleep problems secondary to clinical disorders Interaction of society with sleep (e.g., consequences of shift work, occupational health, public health) The microbiome and sleep Chronotherapy Impact of circadian rhythms on sleep, physiology, cognition and health Mechanisms controlling circadian rhythms, centrally and peripherally Impact of circadian rhythm disruptions (including night shift work, jet lag and social jet lag) on sleep, physiology, cognition and health Behavioral and pharmacological interventions aimed at reducing adverse effects of circadian-related sleep disruption Assessment of technologies and biomarkers for measuring sleep and/or circadian rhythms Epigenetic markers of sleep or circadian disruption.